United Therapeutics (NASDAQ:UTHR) CEO Sells $1,669,200.00 in Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares of the company's stock for a total value of $1,669,200, which represents a 96.85% decrease in their position, leaving them with only 130 shares.
• Despite missing analysts' EPS estimates by $0.39, the company reported a revenue of $798.6 million for the quarter, which is an 11.7% year-over-year increase.
• United Therapeutics has received several changes in analyst ratings, with targets ranging from $328.00 to $575.00, indicating a consensus rating of "Moderate Buy" among analysts.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 4,000 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $417.30, for a total transaction of $1,669,200.00. Following the sale, the chief executive officer owned 130 shares of the company's stock, valued at approximately $54,249. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $19.94 on Tuesday, hitting $434.67. The stock had a trading volume of 697,521 shares, compared to its average volume of 577,028. The firm has a market capitalization of $19.61 billion, a price-to-earnings ratio of 16.96, a P/E/G ratio of 6.37 and a beta of 0.62. The stock's 50 day moving average is $331.90 and its 200-day moving average is $311.38. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the company posted $5.85 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in United Therapeutics during the first quarter valued at approximately $313,000. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after acquiring an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new position in shares of United Therapeutics during the first quarter valued at $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Finally, UBS Group raised their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research report on Thursday, September 4th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.